Trials / Completed
CompletedNCT02223481
Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
A Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study sought to determine whether terbogrel was an effective treatment for primary pulmonary hypertension (PPH) by comparing its efficacy and safety to that of placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terbogrel low dose | |
| DRUG | Terbogrel high dose | |
| DRUG | Placebo |
Timeline
- Start date
- 1998-05-01
- Primary completion
- 1999-09-01
- First posted
- 2014-08-22
- Last updated
- 2014-08-22
Source: ClinicalTrials.gov record NCT02223481. Inclusion in this directory is not an endorsement.